Kronos Bio (KRON) Competitors $0.96 +0.03 (+3.21%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KRON vs. ATAI, TNYA, SOPH, ACRV, ACRS, MOLN, XBIT, BMEA, INBX, and LFVNShould you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include Atai Life Sciences (ATAI), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), Molecular Partners (MOLN), XBiotech (XBIT), Biomea Fusion (BMEA), Inhibrx (INBX), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Kronos Bio vs. Atai Life Sciences Tenaya Therapeutics SOPHiA GENETICS Acrivon Therapeutics Aclaris Therapeutics Molecular Partners XBiotech Biomea Fusion Inhibrx LifeVantage Kronos Bio (NASDAQ:KRON) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Which has more volatility & risk, KRON or ATAI? Kronos Bio has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Is KRON or ATAI more profitable? Atai Life Sciences has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Kronos Bio's return on equity of -64.55% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kronos Bio-867.66% -64.55% -48.18% Atai Life Sciences N/A -65.75%-52.71% Which has stronger valuation & earnings, KRON or ATAI? Atai Life Sciences has lower revenue, but higher earnings than Kronos Bio. Atai Life Sciences is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKronos Bio$9.86M5.86-$112.67M-$1.43-0.67Atai Life Sciences$331K603.28-$40.22M-$0.81-1.47 Does the MarketBeat Community prefer KRON or ATAI? Atai Life Sciences received 310 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 66.33% of users gave Atai Life Sciences an outperform vote while only 65.63% of users gave Kronos Bio an outperform vote. CompanyUnderperformOutperformKronos BioOutperform Votes2165.63% Underperform Votes1134.38% Atai Life SciencesOutperform Votes33166.33% Underperform Votes16833.67% Do analysts rate KRON or ATAI? Kronos Bio currently has a consensus target price of $1.63, indicating a potential upside of 69.64%. Atai Life Sciences has a consensus target price of $9.00, indicating a potential upside of 656.30%. Given Atai Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Atai Life Sciences is more favorable than Kronos Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of KRON or ATAI? 64.1% of Kronos Bio shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 24.4% of Kronos Bio shares are held by company insiders. Comparatively, 31.2% of Atai Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor KRON or ATAI? In the previous week, Kronos Bio's average media sentiment score of 0.76 beat Atai Life Sciences' score of 0.00 indicating that Kronos Bio is being referred to more favorably in the media. Company Overall Sentiment Kronos Bio Positive Atai Life Sciences Neutral SummaryAtai Life Sciences beats Kronos Bio on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRON vs. The Competition Export to ExcelMetricKronos BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.80M$6.57B$5.13B$9.08BDividend YieldN/A2.99%4.91%4.22%P/E Ratio-0.6710.5591.4117.18Price / Sales5.86195.351,113.72116.79Price / CashN/A57.1642.7137.86Price / Book0.355.104.794.78Net Income-$112.67M$151.51M$120.07M$225.60M7 Day Performance-2.25%-2.14%-1.92%-1.23%1 Month Performance9.56%-3.13%11.46%3.36%1 Year Performance-20.18%11.53%30.49%16.59% Kronos Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRONKronos Bio3.3496 of 5 stars$0.96+3.2%$1.63+69.6%-14.5%$57.80M$9.86M-0.67100ATAIAtai Life Sciences1.8864 of 5 stars$1.35-0.7%$9.00+566.7%-9.8%$226.53M$331,000.00-1.6883Positive NewsTNYATenaya Therapeutics3.8979 of 5 stars$2.85+3.6%$17.33+508.2%-33.7%$225.78MN/A-1.91110Analyst ForecastNews CoverageSOPHSOPHiA GENETICS2.445 of 5 stars$3.33+1.5%$6.50+95.2%-25.9%$217.72M$62.37M-3.01520Analyst ForecastNews CoveragePositive NewsACRVAcrivon Therapeutics0.9538 of 5 stars$6.99-1.0%$23.67+238.6%+41.0%$217.64MN/A-2.6158News CoverageACRSAclaris Therapeutics3.8513 of 5 stars$3.03-5.9%$8.80+190.4%+190.9%$216.43M$31.25M-6.1986MOLNMolecular Partners0.344 of 5 stars$5.35-1.5%N/A+17.7%$215.80M$6.00M-2.53180News CoveragePositive NewsXBITXBiotechN/A$6.97+0.3%N/A+61.9%$212.45M$4.01M-6.44100BMEABiomea Fusion3.9017 of 5 stars$5.85+3.7%$39.36+572.9%-69.2%$212.00MN/A-1.4150Analyst ForecastINBXInhibrx1.4866 of 5 stars$14.59-0.2%N/A-49.7%$211.21M$1.57M0.00166LFVNLifeVantage4.5505 of 5 stars$16.80+4.7%N/A+178.9%$210.42M$196.01M50.13260Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies ATAI Competitors TNYA Competitors SOPH Competitors ACRV Competitors ACRS Competitors MOLN Competitors XBIT Competitors BMEA Competitors INBX Competitors LFVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRON) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
